IICS4all: Multi-national Investigator-Initiated Clinical Studies in Cardiovascular, Autoimmune, Metabolic, and Non-Communicable Respiratory Diseases, including Underrepresented Populations
The IICS should be designed as:
- comparative-effectiveness studies and/or
- drug repurposing studies of off-patent drugs
Applicants can make use of existing cohorts, e.g. for designing Trials within Cohorts (TwiCs).
The IICS should have a high public relevance in the fields of the following diseases or conditions (that are of equal importance):
- Cardiovascular diseases
- Metabolic disorders
- Autoimmune diseases
- Non-communicable respiratory diseases
The IICS should primarily address at least one of the abovementioned diseases/conditions, although a proposal can also address several of the mentioned diseases/conditions and/or in combination with related comorbidities.
The IICS should ensure inclusivity and diversity in the study population and also include sex/gender-sensitive, age-specific or other diversity-related aspects, if reasonable.
Please refer to ERA4health website for the complete call text.
ECRIN (European Clinical Research Infrastructure Network) offers support to the planning and conduct of multinational clinical studies and must be contacted by 30 November 2026 if this support if wanted. By using ECRIN services your project is eligible for additional funding, adding 15% to your budget. Contact Norwegian node in ECRIN for this; NorCRIN and European Correspondent Sigrun M. Hjelle, sighje@helse-bergen.no.
Website: https://era4health.eu/calls/iics4all2027.php